Erik Duijvelaar

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

Jurjan Aman, Erik Duijvelaar, Liza Botros et al. · The Lancet Respiratory Medicine · 2021 · 124 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients

Justin de Brabander, Erik Duijvelaar, Job R. Schippers et al. · European Respiratory Journal · 2022 · 54 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Leila N. Atmowihardjo, Job R. Schippers, Erik Duijvelaar et al. · Critical Care · 2023 · 21 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study

Imke H. Bartelink, Pierre M. Bet, Nicolas Widmer et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 20 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Neurofilament light increases over time in severe COVID-19 and is associated with delirium

Patrick Smeele, Lisa Vermunt, Siebe G. Blok et al. · Brain Communications · 2022 · 19 citations · Full text

Medicine, Neurobiology, Neuroscience +15